Adalimumab is effective in patients with inflammatory bowel disease in clinical remission on infliximab

被引：0
|
作者：
Khan, M. [1 ]
Heetun, Z. [1 ]
Moloney, J. [1 ]
Courtney, G. [1 ]
Aftab, A. R. [1 ]
机构：
[1] St Lukes Hosp, Kilkenny, Kilkenny, Ireland
来源：
IRISH JOURNAL OF MEDICAL SCIENCE | 2015年 / 184卷
关键词：
THERAPY; TRIAL;
D O I：
暂无
中图分类号：
R5 [内科学];
学科分类号：
1002 ; 100201 ;
摘要：
5 (14S114)
引用
收藏
页码：S73 / S74
页数：2
相关论文
共 50 条
  • [11] Effectiveness and safety of Adalimumab switch from originator to biosimilar in patients with inflammatory bowel disease in clinical remission
    Gros, B.
    Soto Escribano, P.
    Marin Pedrosa, S.
    Medina Medina, R.
    Benitez, J. M.
    Iglesias-Flores, E.
    JOURNAL OF CROHNS & COLITIS, 2022, 16 : I486 - I486
  • [12] Effectiveness and safety of Adalimumab switch from originator to biosimilar in patients with inflammatory bowel disease in clinical remission
    Gros, B.
    Soto Escribano, P.
    Marin Pedrosa, S.
    Medina Medina, R.
    Benitez, J. M.
    Iglesias-Flores, E.
    JOURNAL OF CROHNS & COLITIS, 2022, 16 : I486 - I486
  • [13] The effects of pregnancy on the pharmacokinetics of infliximab and adalimumab in inflammatory bowel disease
    Seow, C. H.
    Leung, Y.
    Vande Casteele, N.
    Afshar, E. Ehteshami
    Tanyingoh, D.
    Bindra, G.
    Stewart, M. J.
    Beck, P. L.
    Kaplan, G. G.
    Ghosh, S.
    Panaccione, R.
    ALIMENTARY PHARMACOLOGY & THERAPEUTICS, 2017, 45 (10) : 1329 - 1338
  • [14] PROLONGED SCHEDULED THERAPY WITH INFLIXIMAB IN PATIENTS WITH INFLAMMATORY BOWEL DISEASE: EVALUATION OF CLINICAL REMISSION AND MUCOSAL HEALING
    Grossi, L.
    Spezzaferro, M.
    Sacco, L. F.
    Serio, M. E.
    Amitrano, M.
    Cerasa, B.
    Marzio, L.
    DIGESTIVE AND LIVER DISEASE, 2008, 40 : S128 - S129
  • [15] Azathioprine, infliximab, certolizumab, and adalimumab are effective for maintaining remission in Crohn disease
    Marshall, John K.
    ANNALS OF INTERNAL MEDICINE, 2008, 148 (12)
  • [16] Obesity is associated with a higher risk of immunogenicity to adalimumab, but not to infliximab in patients with Inflammatory Bowel Disease
    Mahmoud, R.
    Schultheiss, J.
    Louwers, J.
    van der Kaaij, M.
    van Hellemondt, B.
    Mahmmod, N.
    van Boeckel, P.
    Jharap, B.
    Fidder, H.
    Oldenburg, B.
    JOURNAL OF CROHNS & COLITIS, 2021, 15 : S420 - S421
  • [17] Differential Serum-intestinal Dynamics of Infliximab and Adalimumab in Inflammatory Bowel Disease Patients
    Bar-Yoseph, Haggai
    Blatt, Alexandra
    Gerassy, Shiran
    Pressman, Sigal
    Mousa, Amjad
    Sabo, Edmond
    Waterman, Matti
    Ungar, Bella
    Ben-Horin, Shomron
    Chowers, Yehuda
    JOURNAL OF CROHNS & COLITIS, 2022, 16 (06): : 884 - 892
  • [18] Prior Antibodies to Infliximab or Adalimumab Are Related to Immunogenicity to Vedolizumab in Patients With Inflammatory Bowel Disease
    Papamichael, Konstantinos
    Vande Casteele, Niels
    Abraham, Bincy P.
    Ritter, Timothy
    Jain, Anjali
    Cheifetz, Adam S.
    CLINICAL GASTROENTEROLOGY AND HEPATOLOGY, 2023, 21 (11) : 2978 - +
  • [19] False Positive Infliximab Levels Detected in Patients Treated with Adalimumab for Inflammatory Bowel Disease
    Abraham, Bincy
    Chiorean, Michael
    AMERICAN JOURNAL OF GASTROENTEROLOGY, 2012, 107 : S627 - S627
  • [20] Serum Adalimumab Levels Predict Successful Remission and Safe Deintensification in Inflammatory Bowel Disease Patients in Clinical Practice
    Aguas Peris, Mariam
    Boso, Virginia
    Navarro, Belen
    Marques-Minana, Maria R.
    Bastida, Guillermo
    Beltran, Belen
    Iborra, Marisa
    Saez-Gonzalez, Esteban
    Monte-Boquet, Emilio
    Poveda-Andres, Jose L.
    Nos, Pilar
    INFLAMMATORY BOWEL DISEASES, 2017, 23 (08) : 454 - 460
12345